{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:17:30Z","timestamp":1769552250712,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Blue Cross-Blue Shield of Michigan\/Blue Care Network"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["T32-HL007853"],"award-info":[{"award-number":["T32-HL007853"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s11239-018-1698-y","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T08:58:41Z","timestamp":1528966721000},"page":"316-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the \u201cReal-World\u201d Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7099-5478","authenticated-orcid":false,"given":"Andrew B.","family":"Hughey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaokui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Haymart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Kline-Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Almany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Kozlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Besley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory D.","family":"Krol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Kaatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Froehlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey D.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"issue":"8","key":"1698_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22(8):983\u2013988","journal-title":"Stroke"},{"issue":"8631","key":"1698_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","volume":"333","author":"P Petersen","year":"1989","unstructured":"Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 333(8631):175\u2013179","journal-title":"Lancet"},{"issue":"22","key":"1698_CR3","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","volume":"323","author":"The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators","year":"1990","unstructured":"The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators (1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. New Engl J Med 323(22):1505\u20131511. \n                    https:\/\/doi.org\/10.1056\/NEJM199011293232201","journal-title":"New Engl J Med"},{"issue":"2","key":"1698_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","volume":"84","author":"Stroke Prevention in Atrial Fibrillation Study","year":"1991","unstructured":"Stroke Prevention in Atrial Fibrillation Study (1991) Final results. Circulation 84(2):527\u2013539","journal-title":"Circulation"},{"issue":"20","key":"1698_CR5","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","volume":"327","author":"MD Ezekowitz","year":"1992","unstructured":"Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators et al (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. New Engl J Med 327(20):1406\u20131412. \n                    https:\/\/doi.org\/10.1056\/NEJM199211123272002","journal-title":"New Engl J Med"},{"issue":"8882","key":"1698_CR6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","volume":"342","author":"EAFT (European Atrial Fibrillation Trial) Study Group","year":"1993","unstructured":"EAFT (European Atrial Fibrillation Trial) Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342(8882):1255\u20131262","journal-title":"Lancet"},{"issue":"12","key":"1698_CR7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, Committee R-LS, Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 361(12):1139\u20131151. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0905561","journal-title":"New Engl J Med"},{"issue":"10","key":"1698_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, Investigators RA (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 365(10):883\u2013891. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1009638","journal-title":"New Engl J Med"},{"issue":"11","key":"1698_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, Committees A, Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 365(11):981\u2013992. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"New Engl J Med"},{"issue":"6","key":"1698_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCOUTCOMES.110.937680","volume":"3","author":"MC Fang","year":"2010","unstructured":"Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE (2010) Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 3(6):624\u2013631. \n                    https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.110.937680","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"1698_CR11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.amjcard.2005.09.086","volume":"97","author":"MR Reynolds","year":"2006","unstructured":"Reynolds MR, Shah J, Essebag V, Olshansky B, Friedman PA, Hadjis T, Lemery R, Bahnson TD, Cannom DS, Josephson ME, Zimetbaum P (2006) Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol 97(4):538\u2013543. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2005.09.086","journal-title":"Am J Cardiol"},{"issue":"6","key":"1698_CR12","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1378\/chest.126.6.1938","volume":"126","author":"MW Reynolds","year":"2004","unstructured":"Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, Nalysnyk L (2004) Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 126(6):1938\u20131945. \n                    https:\/\/doi.org\/10.1378\/chest.126.6.1938","journal-title":"Chest"},{"issue":"3","key":"1698_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.18553\/jmcp.2009.15.3.244","volume":"15","author":"WL Baker","year":"2009","unstructured":"Baker WL, Cios DA, Sander SD, Coleman CI (2009) Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Managed Care Pharm 15(3):244\u2013252","journal-title":"J Managed Care Pharm"},{"issue":"1","key":"1698_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11239-012-0766-y","volume":"35","author":"GD Barnes","year":"2013","unstructured":"Barnes GD, Kaatz S, Golgotiu V, Gu X, Leidal A, Kobeissy A, Haymart B, Kline-Rogers E, Kozlowski J, Almany S, Leyden T, Froehlich JB (2013) Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). J Thromb Thrombolysis 35(1):10\u201314. \n                    https:\/\/doi.org\/10.1007\/s11239-012-0766-y","journal-title":"J Thromb Thrombolysis"},{"key":"1698_CR15","unstructured":"Michigan Anticoagulation Quality Improvement Initiative Website (2014) \n                    http:\/\/www.maqi2.org"},{"issue":"15","key":"1698_CR16","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJMc1407908","volume":"371","author":"SJ Connolly","year":"2014","unstructured":"Connolly SJ, Wallentin L, Yusuf S (2014) Additional events in the RE-LY trial. New Engl J Med 371(15):1464\u20131465. \n                    https:\/\/doi.org\/10.1056\/NEJMc1407908","journal-title":"New Engl J Med"},{"issue":"3","key":"1698_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","volume":"159","author":"RD Lopes","year":"2010","unstructured":"Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L, Investigators A (2010) Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159(3):331\u2013339. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2009.07.035","journal-title":"Am Heart J"},{"issue":"22","key":"1698_CR18","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22):2864\u20132870","journal-title":"JAMA"},{"issue":"3","key":"1698_CR19","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69(3):236\u2013239","journal-title":"Thromb Haemost"},{"issue":"4","key":"1698_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. \n                    https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"issue":"11","key":"1698_CR21","doi-asserted-by":"publisher","first-page":"21192126","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, for the Subcommittee on Control of Anticoagulation (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119\u20132126","journal-title":"J Thromb Haemost"},{"issue":"19","key":"1698_CR22","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1161\/CIRCULATIONAHA.112.101808","volume":"126","author":"HG Van Spall","year":"2012","unstructured":"Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ (2012) Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 126(19):2309\u20132316. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.101808","journal-title":"Circulation"},{"issue":"1","key":"1698_CR23","doi-asserted-by":"publisher","first-page":"e000067","DOI":"10.1161\/JAHA.112.000067","volume":"2","author":"DE Singer","year":"2013","unstructured":"Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KA, Investigators RA (2013) Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2(1):e000067. \n                    https:\/\/doi.org\/10.1161\/JAHA.112.000067","journal-title":"J Am Heart Assoc"},{"key":"1698_CR24","volume-title":"Statistics in epidemiology: methods, techniques, and applications","author":"H Sahai","year":"1996","unstructured":"Sahai H, Khurshid A (1996) Statistics in epidemiology: methods, techniques, and applications. CRC Press, Boca Raton"},{"key":"1698_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001768","author":"S Lee","year":"2012","unstructured":"Lee S, Monz BU, Clemens A, Brueckmann M, Lip GY (2012) Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2012-001768","journal-title":"BMJ Open"},{"issue":"5","key":"1698_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1185\/03007995.2013.879529","volume":"30","author":"N Schoof","year":"2014","unstructured":"Schoof N, Schnee J, Schneider G, Gawlik M, Zint K, Clemens A, Bartels DB (2014) Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Curr Med Res Opin 30(5):795\u2013804. \n                    https:\/\/doi.org\/10.1185\/03007995.2013.879529","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"1698_CR27","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.amjmed.2014.05.013","volume":"127","author":"NR Desai","year":"2014","unstructured":"Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, Spettell CM, Brennan TA, Matlin OS, Avorn J, Choudhry NK (2014) Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. Am J Med 127(11):1075\u20131082. \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2014.05.013","journal-title":"Am J Med"},{"issue":"1","key":"1698_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1378\/chest.07-0500","volume":"132","author":"GY Lip","year":"2007","unstructured":"Lip GY (2007) Coronary artery disease and ischemic stroke in atrial fibrillation. Chest 132(1):8\u201310. \n                    https:\/\/doi.org\/10.1378\/chest.07-0500","journal-title":"Chest"},{"issue":"11","key":"1698_CR29","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.amjcard.2004.02.047","volume":"93","author":"DS Conway","year":"2004","unstructured":"Conway DS, Lip GY (2004) Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). Am J Cardiol 93(11):1422\u20131425. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2004.02.047","journal-title":"Am J Cardiol"},{"issue":"1","key":"1698_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1378\/chest.06-2733","volume":"132","author":"CW Siu","year":"2007","unstructured":"Siu CW, Jim MH, Ho HH, Miu R, Lee SW, Lau CP, Tse HF (2007) Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. Chest 132(1):44\u201349. \n                    https:\/\/doi.org\/10.1378\/chest.06-2733","journal-title":"Chest"},{"issue":"9","key":"1698_CR31","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehn579","volume":"30","author":"J Schmitt","year":"2009","unstructured":"Schmitt J, Duray G, Gersh BJ, Hohnloser SH (2009) Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 30(9):1038\u20131045. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehn579","journal-title":"Eur Heart J"},{"issue":"5","key":"1698_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/eurheartj\/ehu359","volume":"36","author":"BA Steinberg","year":"2015","unstructured":"Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey KW, Fox KA, Califf RM, Piccini JP, Committee R-AS, Investigators (2015) Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF trial. Eur Heart J 36(5):288\u2013296. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehu359","journal-title":"Eur Heart J"},{"issue":"5","key":"1698_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/eurheartj\/ehu307","volume":"36","author":"T Vanassche","year":"2015","unstructured":"Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A, Diaz R, Hohnloser SH, Lewis BS, Shestakovska O, Wang J, Connolly SJ (2015) Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 36(5):281\u2013287. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehu307","journal-title":"Eur Heart J"},{"issue":"31","key":"1698_CR34","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1093\/eurheartj\/eht135","volume":"34","author":"SM Al-Khatib","year":"2013","unstructured":"Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, Ezekowitz J, Alings M, Yang H, Alexander JH, Flaker G, Hanna M, Granger CB (2013) Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J 34(31):2464\u20132471. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/eht135","journal-title":"Eur Heart J"},{"issue":"1","key":"1698_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1345\/aph.1R515","volume":"47","author":"M Raji","year":"2013","unstructured":"Raji M, Lowery M, Lin YL, Kuo YF, Baillargeon J, Goodwin JS (2013) National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. Ann Pharmacother 47(1):35\u201342. \n                    https:\/\/doi.org\/10.1345\/aph.1R515","journal-title":"Ann Pharmacother"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-018-1698-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1698-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1698-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T07:58:22Z","timestamp":1589702302000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-018-1698-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1698"],"URL":"https:\/\/doi.org\/10.1007\/s11239-018-1698-y","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,14]]},"assertion":[{"value":"14 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Steve Almany: Grant support from Boston Scientific Watchman, Michigan Anticoagulation Quality, and Abbott Absorb trial. Consultant for Kona, Trice Orthopedics, and Micardia. Ownership\/partnership\/principal with Biostar Ventures and Ablative Solutions. Scott Kaatz: Grant support from Boehringer-Ingelheim, Bristol-Myers Squibb, Bayer\/Jansen\/Johnson and Johnson, Eisai, Iverson Genetics Diagnostics\/Medicare, National Institute of Health, Canadian Institute of Health Research, Blue Cross\/Blue Shield of Michigan. Speaker honorarium from Jansen\/Johnson and Johnson, Boehringer-Ingelheim, and Bristol-Myers Squibb. Consultant for Boehringer Ingelheim, Bristol-Myers Squibb\/Pfizer, Jansen\/Johnson and Johnson, and Daiichi Sankyo. Non-profit board membership with AC Forum, National Certification Board of Anticoagulation Providers, and National Blood Clot Alliance Medical and Scientific Advisory Board. James B. Froehlich: Consultant for Merck, Bristol-Meyers Squibb, Pfizer, Sanofi-Aventis, Janssen Pharamaceuticals, Aralez and Ortho-McNeil. Research grants from Sanofi-Aventis, Blue Cross\/Blue Shield of Michigan, Mardigian Foundation, Fibromuscular Disease Society of America. Geoffrey D. Barnes: Research grant support from Bristol Meyers Squibb\/Pfizer and Blue Cross\/Blue Shield of Michigan. Consultant for Portola and Aralez. Andrew B. Hughey, Xiaokui Gu, Brian Haymart, Eva Kline-Rogers, Jay Kozlowski, Dennis Besley, Gregory D. Krol, Syed Ahsan, declares that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}